Surface evaluations of a nanocomposite after different finishing and polishing systems for anterior and posterior restorations

This study aims to evaluate the effects of different finishing and polishing (F/P) systems on gloss and surface morphology of a new nanocomposite. Thirty discs of Filtek Universal Restorative material (3 M, ESPE) were prepared and divided into six groups (n = 5). Group A and B followed F/P protocols for anterior restorations, whereas Group C and D for posterior ones. Group E represented the control (covered by Mylar strip) and Group F represented the nanocomposite placement by means of clinical hand instruments; Groups E and F did not undergo F/P procedures. Among the polished groups, Group B showed the highest values (68.54 ± 7.54 GU), followed by Group A and D (46.87 ± 5.52 GU; 53.76 ± 2.65 GU). Finally, Group C (37.38 ± 4.93 GU) displayed the lowest results. Overall, Group E showed the highest gloss values (93.45 ± 8.27 GU), while Group F presented the lowest ones (1.74 ± 0.64 GU). Surface analysis revealed that Group A, C, and D displayed a smooth surface. Group B showed the lowest irregularities. Group E exhibited the most uniform superficial morphology. On the other hand, Group F displayed the most irregular one. In conclusion, using the tested material, only two protocols achieved appropriate gloss values. Then, clinicians might use the protocols of Group B and Group D, for anterior and posterior restorations, respectively

Investigation of the Feasibility of Ventricular Delivery of Resveratrol to the Microelectrode Tissue Interface

(1) Background: Intracortical microelectrodes (IMEs) are essential to basic brain research and clinical brain–machine interfacing applications. However, the foreign body response to IMEs results in chronic inflammation and an increase in levels of reactive oxygen and nitrogen species (ROS/RNS). The current study builds on our previous work, by testing a new delivery method of a promising antioxidant as a means of extending intracortical microelectrodes performance. While resveratrol has shown efficacy in improving tissue response, chronic delivery has proven difficult because of its low solubility in water and low bioavailability due to extensive first pass metabolism. (2) Methods: Investigation of an intraventricular delivery of resveratrol in rats was performed herein to circumvent bioavailability hurdles of resveratrol delivery to the brain. (3) Results: Intraventricular delivery of resveratrol in rats delivered resveratrol to the electrode interface. However, intraventricular delivery did not have a significant impact on electrophysiological recordings over the six-week study. Histological findings indicated that rats receiving intraventricular delivery of resveratrol had a decrease of oxidative stress, yet other biomarkers of inflammation were found to be not significantly different from control groups. However, investigation of the bioavailability of resveratrol indicated a decrease in resveratrol accumulation in the brain with time coupled with inconsistent drug elution from the cannulas. Further inspection showed that there may be tissue or cellular debris clogging the cannulas, resulting in variable elution, which may have impacted the results of the study. (4) Conclusions: These results indicate that the intraventricular delivery approach described herein needs further optimization, or may not be well suited for this application

Neural engineering: the process, applications, and its role in the future of medicine

ObjectiveRecent advances in neural engineering have restored mobility to people with paralysis, relieved symptoms of movement disorders, reduced chronic pain, restored the sense of hearing, and provided sensory perception to individuals with sensory deficits.ApproachThis progress was enabled by the team-based, interdisciplinary approaches used by neural engineers. Neural engineers have advanced clinical frontiers by leveraging tools and discoveries in quantitative and biological sciences and through collaborations between engineering, science, and medicine. The movement toward bioelectronic medicines, where neuromodulation aims to supplement or replace pharmaceuticals to treat chronic medical conditions such as high blood pressure, diabetes and psychiatric disorders is a prime example of a new frontier made possible by neural engineering. Although one of the major goals in neural engineering is to develop technology for clinical applications, this technology may also offer unique opportunities to gain insight into how biological systems operate.Main resultsDespite significant technological progress, a number of ethical and strategic questions remain unexplored. Addressing these questions will accelerate technology development to address unmet needs. The future of these devices extends far beyond treatment of neurological impairments, including potential human augmentation applications. Our task, as neural engineers, is to push technology forward at the intersection of disciplines, while responsibly considering the readiness to transition this technology outside of the laboratory to consumer products.SignificanceThis article aims to highlight the current state of the neural engineering field, its links with other engineering and science disciplines, and the challenges and opportunities ahead. The goal of this article is to foster new ideas for innovative applications in neurotechnology